Drug Database
Back to search

Finland· FI-REL-REL53765

Emgality

A galcanezumab product containing galcanezumab, registered in Finland by Eli Lilly Nederland B.V.. The same ATC class is registered in 13 of our 19 countries.

ATC N02CD02

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedEmgalityATCN02CD02REGISTER NO.FI-REL-REL53765PACKS LISTED0CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about galcanezumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Galcanezumab is registered in 13 of 19 countries.

Countries holding a registration under ATC N02CD02 (galcanezumab), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 9 of them publish a price we can compare per daily dose
Search galcanezumab products by name

Galcanezumab · ATC N02CD02

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Active substance
Galcanezumab
Manufacturer
Eli Lilly Nederland B.V.
Country
Finland (FI)
ATC code
N02CD02
ATC class
Galcanezumab
Defined daily dose
4 mg, P
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Galcanezumab in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All galcanezumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Emgality
  • Liechtenstein · Emgality
  • Norway · Emgality

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ee437e3b-5c0f-4b95-bd7c-4a3ef60c0710
GET /v1/drugs/ee437e3b-5c0f-4b95-bd7c-4a3ef60c0710?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "4",
  "form": "injektioneste, liuos, esitäytetty ruisku",
  "route": "Ihon alle",
  "ddd_unit": "mg",
  "strength": "120 mg",
  "atc_label": "galkanetsumabi",
  "ma_number": null,
  "auth_status": "Myyntilupa myönnetty",
  "eu_ma_number": "EU/1/18/1330/003-004, 006",
  "fimea_rel_id": "REL53765",
  "authorised_at": "2018-11-14"
}
API referenceMCP serverPlans

See everything about galcanezumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console